$5.55
1.42% today
NYSE, Aug 18, 10:00 pm CET
ISIN
US05380C1027
Symbol
RCEL

AVITA Therapeutics Target price 2025 - Analyst rating & recommendation

AVITA Therapeutics Classifications & Recommendation:

Buy
77%
Hold
15%
Sell
8%

AVITA Therapeutics Price Target

Target Price $16.83
Price $5.55
Potential
Number of Estimates 6
6 Analysts have issued a price target AVITA Therapeutics 2026 . The average AVITA Therapeutics target price is $16.83. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 13 analysts: 10 Analysts recommend AVITA Therapeutics to buy, 2 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the AVITA Therapeutics stock has an average upside potential 2026 of . Most analysts recommend the AVITA Therapeutics stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 64.25 100.98
28.14% 57.17%
EBITDA Margin -85.40% -23.20%
2.64% 72.83%

9 Analysts have issued a sales forecast AVITA Therapeutics 2025 . The average AVITA Therapeutics sales estimate is

$101m
Unlock
. This is
34.86% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$111m 47.64%
Unlock
, the lowest is
$90.4m 20.70%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $64.3m 28.14%
2025
$101m 57.17%
Unlock
2026
$138m 36.69%
Unlock
2027
$184m 33.14%
Unlock
2028
$284m 54.49%
Unlock
2029
$353m 24.30%
Unlock
2030
$403m 14.20%
Unlock
2031
$477m 18.44%
Unlock
2032
$581m 21.77%
Unlock

6 Analysts have issued an AVITA Therapeutics EBITDA forecast 2025. The average AVITA Therapeutics EBITDA estimate is

$-23.4m
Unlock
. This is
112.63% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-21.9m 111.78%
Unlock
, the lowest is
$-24.0m 112.94%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-54.9m 31.52%
2025
$-23.4m 57.30%
Unlock
2026
$-10.5m 55.32%
Unlock
2027
$3.3m 131.65%
Unlock
2028
$37.1m 1,018.80%
Unlock
2029
$43.5m 17.36%
Unlock
2030
$49.7m 14.32%
Unlock
2031
$55.5m 11.50%
Unlock
2032
$61.1m 10.13%
Unlock

EBITDA Margin

2024 -85.40% 2.64%
2025
-23.20% 72.83%
Unlock
2026
-7.59% 67.28%
Unlock
2027
1.80% 123.72%
Unlock
2028
13.06% 625.56%
Unlock
2029
12.33% 5.59%
Unlock
2030
12.34% 0.08%
Unlock
2031
11.62% 5.83%
Unlock
2032
10.51% 9.55%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -2.39 -0.70
70.71% 70.71%
P/E negative
EV/Sales 1.65

9 Analysts have issued a AVITA Therapeutics forecast for earnings per share. The average AVITA Therapeutics EPS is

$-0.70
Unlock
. This is
64.47% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.19 90.36%
Unlock
, the lowest is
$-0.97 50.76%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-2.39 70.71%
2025
$-0.70 70.71%
Unlock
2026
$-0.18 74.29%
Unlock
2027
$0.07 138.89%
Unlock
2028
$4.40 6,185.71%
Unlock
2029
$5.65 28.41%
Unlock
2030
$6.93 22.65%
Unlock
2031
$8.80 26.98%
Unlock
2032
$11.36 29.09%
Unlock

P/E ratio

Current -2.86 42.07%
2025
-8.07 182.38%
Unlock
2026
-31.94 295.79%
Unlock
2027
84.92 365.87%
Unlock
2028
1.28 98.49%
Unlock
2029
1.00 21.88%
Unlock
2030
0.81 19.00%
Unlock
2031
0.64 20.99%
Unlock
2032
0.50 21.88%
Unlock

Based on analysts' sales estimates for 2025, the AVITA Therapeutics stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.22 48.97%
2025
1.65 25.81%
Unlock
2026
1.20 26.84%
Unlock
2027
0.90 24.90%
Unlock
2028
0.59 35.27%
Unlock
2029
0.47 19.55%
Unlock
2030
0.41 12.44%
Unlock
2031
0.35 15.56%
Unlock
2032
0.29 17.88%
Unlock

P/S ratio

Current 2.01 56.20%
2025
1.49 25.85%
Unlock
2026
1.09 26.84%
Unlock
2027
0.82 24.89%
Unlock
2028
0.53 35.28%
Unlock
2029
0.43 19.54%
Unlock
2030
0.37 12.44%
Unlock
2031
0.32 15.57%
Unlock
2032
0.26 17.87%
Unlock

Current AVITA Therapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Lake Street
Locked
Locked
Locked Aug 11 2025
D. Boral Capital
Locked
Locked
Locked Aug 08 2025
D. Boral Capital
Locked
Locked
Locked Jun 10 2025
D. Boral Capital
Locked
Locked
Locked Jun 06 2025
D. Boral Capital
Locked
Locked
Locked Apr 10 2025
D. Boral Capital
Locked
Locked
Locked Apr 04 2025
D. Boral Capital
Locked
Locked
Locked Mar 18 2025
Analyst Rating Date
Locked
Lake Street:
Locked
Locked
Aug 11 2025
Locked
D. Boral Capital:
Locked
Locked
Aug 08 2025
Locked
D. Boral Capital:
Locked
Locked
Jun 10 2025
Locked
D. Boral Capital:
Locked
Locked
Jun 06 2025
Locked
D. Boral Capital:
Locked
Locked
Apr 10 2025
Locked
D. Boral Capital:
Locked
Locked
Apr 04 2025
Locked
D. Boral Capital:
Locked
Locked
Mar 18 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today